An Open-Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation-Positive Tumor.
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Dabrafenib (Primary)
- Indications Tumours
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 04 Apr 2012 Results presented at the 103rd Annual Meeting of the American Association for Cancer Research.
- 20 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 20 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.